Flash Drives and Funny Numbers: What Elevance Health’s Earnings Really Reveal

Key Takeaways

• Elevance reported adjusted EPS $12.58, beating expectations
• CMS estimates $935M liability for improper Medicare Advantage billing
• Medicare Advantage membership fell 15.8% YoY to 1.9M
• MLR climbed to 86.8%, above UnitedHealth's 83.9%
• Elevance raised full-year adjusted EPS guidance to $26.75

Pulse Analysis

The Medicare Advantage risk‑adjustment system rewards insurers for sicker enrollee profiles, but it also places the onus of accurate diagnosis coding on the carriers. Elevance Health’s use of encrypted USB flash drives instead of CMS‑mandated electronic submissions for seven years triggered a "substantial and persistent non‑compliance" finding, prompting a $935 million estimated liability. This episode underscores how data‑integrity lapses can translate into massive federal recoveries, especially as the Medicare Payment Advisory Commission estimates the government overpays the program by tens of billions annually.

Elevance’s financial picture contrasts sharply with UnitedHealth Group, the industry’s largest player. UnitedHealth posted $111.7 billion in revenue, an adjusted EPS of $7.23 and a medical loss ratio (MLR) of 83.9%, while Elevance’s MLR rose to 86.8% amid declining Medicare Advantage enrollment (down 15.8% to 1.9 million) and a 4.6% drop in Medicaid members. The higher MLR reflects both elevated Medicaid costs and the fallout from the Medicare billing dispute, compressing GAAP earnings per share to $8.00. Yet the market’s reaction was muted—Elevance shares edged up modestly, whereas UnitedHealth’s stock jumped over 2% on the same day, signaling investor confidence in the larger insurer’s growth trajectory and acquisition strategy.

Looking ahead, Elevance faces a tight timeline to satisfy CMS compliance directives by July 31, with the threat of sanctions if corrective steps are incomplete. The company’s emphasis on AI‑driven denial reduction could improve future cost structures, but without transparent methodology the claim remains speculative. For the broader health‑insurance sector, the episode reinforces the importance of robust data governance and the financial materiality of regulatory risk, factors that investors will scrutinize as Medicare Advantage and Medicaid continue to dominate profit margins.